HCM-mutation G716R in β-myosin alters contractile function and responsiveness to mavacamten of human ventricular myofibrils
HCM-mutation G716R in β-myosin alters contractile function and responsiveness to mavacamten of human ventricular myofibrils
Brunkhorst, A.; Holler, T.; Piep, B.; Francino, A.; dos Remedios, C. G.; Kraft, T.; Iorga, B.
AbstractEffects of the hypertrophic cardiomyopathy (HCM) associated mutation Gly716Arg in {beta}-myosin at the sarcomeric level are unresolved. To further understand HCM-pathomechanisms in relation to modern treatment, we investigated the effect of this mutation in subcellular myofibrils isolated from HCM-patient myocardium compared to myofibrils from healthy donor hearts and tested how mavacamten influences force-related parameters. Mavacamten is a state-of-the-art myosin inhibitor aimed to treat ventricular hypercontractility of symptomatic HCM patients. Compared with donor myofibrils, patient myofibrils developed similar isometric forces, while kinetics of maximum force generation and particularly of relaxation were slower. Relaxation impairment was exacerbated when patient myofibrils were incompletely relaxed to mimic residual diastolic calcium levels. Inhibitory effects of mavacamten were dependent on force activation level and significantly less efficient in patient myofibrils. While the drug accelerated full relaxation of donor myofibrils, the slowing down effect of the mutation was not reversed by the drug in patient myofibrils. At partial relaxation, impairment was further aggravated by mavacamten in patient myofibrils. This study suggests that HCM-associated mutation G716R in {beta}-myosin does not evoke gain-of-function in human left ventricular myofibrils, and impaired relaxation could not be rescued by mavacamten. Our findings suggest that HCM-associated mutations may modulate myofibrillar sensitivity to mavacamten, providing a potential mechanistic explanation for differences in treatment response. Studies such as the present one highlight the importance of mutation-dependent sarcomeric properties in understanding variability in responses to myosin modulators and potentially informing more individualized treatment strategies.